| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.SEMARTHRIT.2010.11.002 |
| P698 | PubMed publication ID | 21277618 |
| P50 | author | Manuel Ramos-casals | Q42646201 |
| Pilar Brito Zerón | Q56956066 | ||
| P2093 | author name string | Xavier Bosch | |
| Soledad Retamozo | |||
| Candido Diaz-Lagares | |||
| Albert Bove | |||
| Marta Perez-de-Lis | |||
| Roberto Perez-Alvarez | |||
| Jose M Pego-Reigosa | |||
| P433 | issue | 2 | |
| P921 | main subject | interstitial lung disease | Q1153419 |
| TNF | Q18032037 | ||
| P304 | page(s) | 256-264 | |
| P577 | publication date | 2011-02-01 | |
| P1433 | published in | Seminars in Arthritis and Rheumatism | Q15761553 |
| P1476 | title | Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases | |
| P478 | volume | 41 |
| Q92573817 | A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα |
| Q40578208 | A stonemason with accelerated silicosis in the setting of tumour necrosis factor alpha inhibitor therapy |
| Q51625080 | Acute exacerbation of rheumatoid interstitial lung disease during the maintenance therapy with certolizumab pegol. |
| Q89703735 | Adalimumab induced interstitial lung disease |
| Q33824393 | Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. |
| Q43144548 | Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease |
| Q64097919 | Biologic Treatments in Interstitial Lung Diseases |
| Q39100810 | Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies |
| Q38284035 | Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases |
| Q64917346 | Case of drug-induced interstitial lung disease secondary to adalimumab. |
| Q46085098 | Chronic cough and an atypical pattern of peripheral pulmonary opacities: A case report secondary to suspected drug onset |
| Q39205697 | Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis. |
| Q40884254 | Distinct immunologic and radiographic patterns in etanercept-induced lung injury |
| Q33657810 | Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability. |
| Q57463653 | Drug-Induced Interstitial Lung Disease: A Systematic Review |
| Q38819214 | Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre |
| Q91905551 | Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? |
| Q38711889 | Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis |
| Q38632441 | Idiopathic non-specific interstitial pneumonia |
| Q36270376 | Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study |
| Q35763043 | Interstitial Lung Disease of the UIP Variant as the Only Presenting Symptom of Rheumatoid Arthritis |
| Q38191199 | Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced |
| Q40136860 | Interstitial lung disease in rheumatoid arthritis in the era of biologics |
| Q47372819 | Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review |
| Q38125245 | Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis |
| Q90106982 | Management issues in rheumatoid arthritis-associated interstitial lung disease |
| Q26781712 | Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis |
| Q26766526 | Management of interstitial lung disease associated with connective tissue disease |
| Q26785617 | Managing comorbidities in idiopathic pulmonary fibrosis |
| Q59074825 | New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review |
| Q51739890 | Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. |
| Q37118882 | Noninfectious interstitial lung disease during infliximab therapy: case report and literature review |
| Q42434620 | Organizing Pneumonia in a Patient with Quiescent Crohn's Disease. |
| Q90616003 | Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours |
| Q34071762 | Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis |
| Q40750800 | Pulmonary implications in inflammatory bowel disease: not a rare event |
| Q50101241 | Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts |
| Q33711158 | Risk Factors for the Mortality of Pneumocystis jirovecii Pneumonia in Non-HIV Patients Who Required Mechanical Ventilation: A Retrospective Case Series Study |
| Q48144965 | Safety of biologics in psoriasis. |
| Q38099248 | Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies |
| Q40683836 | Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease |
| Q43259442 | Stop Being So Sensitive: An Exceptionally Rare Report of Ustekinumab-Induced Sub-acute Hypersensitivity Pneumonitis |
| Q99565925 | The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients |
| Q26861557 | The multifaceted aspects of interstitial lung disease in rheumatoid arthritis |
| Q28082021 | The role of biologics in treatment of connective tissue disease-associated interstitial lung disease |
| Q38173669 | The safety of biologic therapies in RA-associated interstitial lung disease |
| Q38979114 | Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review |
| Q92384589 | Thoracic Manifestations of Rheumatoid Arthritis |
| Q33907242 | Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view |
| Q26775753 | Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review |
| Q51297193 | Use of biologics and other novel therapies for the treatment of systemic sclerosis. |
| Q51691476 | Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. |
| Q36513081 | Vasculitis associated with tumor necrosis factor-α inhibitors |
| Q90483214 | Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease |
Search more.